BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34854544)

  • 21. [Clinicopathological features of inflammatory myofibroblastic tumor].
    Zhu Y; Ding Y; Song GX; Li X; Ding R; Fan QH; Gong QX
    Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):194-200. PubMed ID: 33677881
    [No Abstract]   [Full Text] [Related]  

  • 22. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
    Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM
    Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory myofibroblastic tumor of bone harboring an ALK gene amplification.
    Wang K; Guo R; Siegal GP; Wei S
    Pathol Res Pract; 2019 Sep; 215(9):152535. PubMed ID: 31326196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT).
    Ingley KM; Hughes D; Hubank M; Lindsay D; Plumb A; Cox R; Chesler L; Strauss SJ
    Lung Cancer; 2021 Aug; 158():151-155. PubMed ID: 34059352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammatory myofibroblastic tumors-A retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe.
    Kube S; Vokuhl C; Dantonello T; Scheer M; Hallmen E; Feuchtgruber S; Escherich G; Niggli F; Kuehnle I; von Kalle T; Bielack S; Klingebiel T; Koscielniak E
    Pediatr Blood Cancer; 2018 Jun; 65(6):e27012. PubMed ID: 29480552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy.
    Baranov E; Winsnes K; O'Brien M; Voss SD; Church AJ; Janeway KA; DuBois SG; Davis JL; Al-Ibraheemi A
    Histopathology; 2022 Aug; 81(2):215-227. PubMed ID: 35543076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report.
    Comandini D; Catalano F; Grassi M; Pesola G; Bertulli R; Guadagno A; Spina B; Mascherini M; De Cian F; Pistoia F; Rebuzzi SE
    Front Oncol; 2021; 11():658327. PubMed ID: 34211840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anaplastic lymphoma kinase inhibitor therapy in the treatment of inflammatory myofibroblastic tumors in pediatric patients: Case reports and literature review.
    Craig E; Wiltsie LM; Beaupin LK; Baig A; Kozielski R; Rothstein DH; Li V; Twist CJ; Barth M
    J Pediatr Surg; 2021 Dec; 56(12):2364-2371. PubMed ID: 33676744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALK Immunoexpression is Specific for Inflammatory Myofibroblastic Tumor Among Vulvovaginal Mesenchymal Neoplasms.
    Bowman CJ; Medeiros F; Fadare O; Sangoi AR; Horvai AE; Devine WP; McCluggage WG; Rabban JT
    Int J Gynecol Pathol; 2023 Jan; 42(1):1-10. PubMed ID: 35180768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammatory myofibroblastic tumors: recent progress and future of targeted therapy.
    Nakano K
    Jpn J Clin Oncol; 2023 Oct; 53(10):885-892. PubMed ID: 37394916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors.
    Preobrazhenskaya EV; Iyevleva AG; Suleymanova AM; Tiurin VI; Mitiushkina NV; Bizin IV; Ivanstov AO; Gorustovich OA; Shelekhova KV; Kachanov DY; Varfolomeeva SR; Roschin VY; Kazakova AN; Litvinov DV; Shamanskaya TV; Savelov NA; Suspitsin EN; Imyanitov EN
    Pediatr Blood Cancer; 2020 May; 67(5):e28220. PubMed ID: 32064735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infantile Inflammatory Myofibroblastic Tumor of Spleen.
    Thirunavukkarasu B; Roy PS; Gupta K; Sekar A; Bansal D
    Fetal Pediatr Pathol; 2022 Jun; 41(3):475-479. PubMed ID: 33095087
    [No Abstract]   [Full Text] [Related]  

  • 34. Inflammatory myofibroblastic tumor of the lung in children: anaplastic lymphoma kinase (ALK) expression and clinico-pathological correlation.
    Siminovich M; Galluzzo L; López J; Lubieniecki F; de Dávila MT
    Pediatr Dev Pathol; 2012; 15(3):179-86. PubMed ID: 22280150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
    Leal JL; Peters G; Szaumkessel M; Leong T; Asadi K; Rivalland G; Do H; Senko C; Mitchell PL; Quing CZ; Dobrovic A; Thapa B; John T
    Lung Cancer; 2020 Aug; 146():154-159. PubMed ID: 32540558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report.
    Takahashi A; Kurosawa M; Uemura M; Kitazawa J; Hayashi Y
    J Int Med Res; 2018 Aug; 46(8):3498-3503. PubMed ID: 29900760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring
    Han Q; He X; Cui L; Qiu Y; Li Y; Chen H; Zhang H
    Front Med (Lausanne); 2022; 9():826705. PubMed ID: 35280868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
    Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic options in inoperable ROS1-rearranged inflammatory myofibroblastic tumor of the tongue in a child: a case report and literature review.
    Styczewska M; Patel A; Jaskulowska J; Godzinski J; Swieton D; Wasag B; Dass J; Bien E; Krawczyk MA
    Anticancer Drugs; 2021 Nov; 32(10):1111-1115. PubMed ID: 34145176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
    Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.